Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

• Status: Completed
• Trial end date: 2010-12-01

Summary

To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)

• Phase: Phase 2

Details

• Lead Sponsor: Stanford University
• Collaborators: National Cancer Institute (NCI); The Leukemia and Lymphoma Society
• Treatments: Acetaminophen; Antilymphocyte Serum; Cyclosporine; Cyclosporins; Diphenhydramine; Granisetron; Hydrocortisone; Lenograstim; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Promethazine; Rituximab; Thymoglobulin